CytomX Therapeutics
CTMX
90 hedge funds and large institutions have $343M invested in CytomX Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 15 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 14
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
7.76% more ownership
Funds ownership: 52.39% → 60.15% (+7.8%)
5% more funds holding
Funds holding: 86 → 90 (+4)
3% more capital invested
Capital invested by funds: $332M → $343M (+$11.1M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.1M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$9.46M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.35M |
| 4 |
Renaissance Technologies
New York
|
+$2.65M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.81M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.11M |
| 3 |
MBT
Montecito Bank & Trust
Santa Barbara,
California
|
-$1.78M |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$1.46M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.29M |
CTMX Hedge Fund Activity: Q2 2017 in Review
90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2017, worth a combined $343M — up 3.4% from $332M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CTMX positions and 15 closed out — a net gain of 4 holders — while 42 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Deerfield Management, cutting an estimated $2.81M.
- 90 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2017, up from 86 in Q1 2017.
- Funds reported $343M of CytomX Therapeutics stock for Q2 2017, up 3.4% quarter-over-quarter.
- 19 funds opened new CytomX Therapeutics positions in Q2 2017 and 15 closed out, a net change of +4 holders.
- The largest CytomX Therapeutics buyer in Q2 2017 was BlackRock, an estimated $12.1M added.
- The largest CytomX Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $2.81M sold.
Based on aggregated 13F filings for Q2 2017.